Team Begins Defining Cancer Risk Patterns for Distinct BRCA1, BRCA2 Mutations | GenomeWeb

NEW YORK (GenomeWeb) – In a study appearing online today in the Journal of the American Medical Association, researchers began to tease apart the differences in breast and ovarian cancer risk for women carrying various BRCA1 and/or BRCA2 gene mutations.

The international team, which included members of the "Consortium of Investigators of Modifiers of BRCA" (CIMBA) group, considered documented disease patterns for tens of thousands of women with BRCA1 or BRCA2 mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy.